CA1201001

A Phase 1/2 Study of BMS-986449 Alone and in Combination with Nivolumab in Participants with Advanced Solid Tumors

  • Code NKI: M23CAS
  • Code firma: CA1201001
  • Code clinicaltrials.gov: NCT05888831

Principal Investigator

Dr. G. Ruiter

Drugs

BMS-986449 (HELIOS degrader) +/- nivolumab

  • NSCLC, TNBC – open
  • Prostate cancer, melanoma – closed

Summary

The purpose of this study is to evaluate the safety and efficacy of BMS-986449 alone and in combination with nivolumab in participants with advanced solid tumors.

Read more on clinicaltrials.gov